blog.aids.gov — HIV Policy & Programs. Research. New Media.
HIV Policy & Programs. Research. New Media.
Today the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), released findings from a large-scale clinical study. This study found that men and women living with HIV who took oral antiretroviral medicines when their immune systems were relatively healthy, were able to reduce the risk of transmitting…
Co-authored by Carole Heilman, Ph.D., Director of NIAID’s Division of Microbiology and Infectious Diseases Over the course of the past two decades the National Institute of Allergy and Infectious Diseases (NIAID) has developed an extensive set of networks to conduct clinical trials related to HIV/AIDS. These networks have helped to develop effective treatments for AIDS,…
Our colleague Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases (NIAID) will appear tonight on "Hope Survives: 30 Years of AIDS," an hour-long special on Anderson Cooper 360° at 9pm ET on CNN. The program will focus on the role stigma continues to play in the spread of HIV, and prevention and…
As the AIDS.gov blog's fourth year begins, we at AIDS.gov are taking time to reflect on 2010 and look to the year ahead. As we continue to integrate monitoring and evaluation into our work, we thought that the New Year provided a nice benchmark to look more closely at our blog. For us, the blog…
Today, the New England Journal of Medicine published research findings from the iPrEx study funded by the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation testing the efficacy of pre-exposure prophylaxis (PrEP). The study is a major step forward in our ability to prevent new HIV infections. The study found that…
WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research. The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…
The National Institutes of Health National Institute of Allergy and Infectious Diseases just made a significant announcement on pre-exposure prophylaxis (PrEP). I am proud to share this important update from the NIH with our blog readers. Learn more by reading this Q&A.
On Tuesday, October 26, more than 300 representatives from our current HIV clinical trial networks, the infectious diseases research community, and HIV advocacy groups attended the “Town Hall Meeting to Examine the Restructuring of the NIAID Clinical Trials Networks.” The goals of the meeting were to: Provide NIAID’s overarching vision for the future of its…
